The financing round was led by Socii Capital with backing from Autodesk, Saint-Gobain and other investors.
"We have been fortunate to work with global industry leaders who share our vision for innovative construction methods and a productised supply chain. This latest fundraising gives us further confidence that KOPE will support those in our industry looking to adopt prefabrication and offsite manufacturing. With these key industry partners and their broad experience, we are excited about this next phase of our journey."
Octopus Ventures led the seed financing, with participation from Horizons Ventures, Verve Ventures, and Air Street Capital, to commercialise live cell imaging technology.
"University spin-outs like CellVoyant are at the heart of the UK’s thriving biotech ecosystem. CellVoyant sets a new standard in precision and reliability for predicting and controlling stem cell behaviour, which will make cell therapies more accessible to those who need them. We are thrilled to invest into a company that is transforming how patients can benefit from life-changing treatments."
The seed round was supported by Scottish angels, existing shareholders, and a Denver family office.
"Having already established the leading position in the digital whisky space; this new capital allows us to cement our market share and grow our consumer audience into new territories. We’re hugely excited to be heading Stateside in 2024!"
The financing round was led by ACF Investors with participation from Nauta Capital, Ascension Ventures, and several strategic angels.
"Against the current zeitgeist of increasing privacy regulations and data restrictions by platforms, there is an urgent need for innovative solutions that empower advertisers without compromising user privacy. This investment is a testament to our foresight in on-device AI and privacy-focused technologies, setting the stage for our global product and commercial expansion plans."
The funding round was led by Eos Advisory and includes participation from the Scottish National Investment Bank.
"This funding round marks an important milestone for Cumulus, as oncology remains a critical area of scientific innovation and unmet medical need. At Cumulus, we're not only innovating at the scientific level but also offering a uniquely differentiated process for decision-making and prioritisation in drug discovery and development. The business model enables only the strongest science to be translated from discovery into clinical trials. Our portfolio approach aims to enhance the ultimate success rate in cancer therapy development, which currently remains unacceptably low. It also provides an alternative approach to the de-risking of early-stage oncology investment. We are grateful for the support from Eos and the Scottish National Investment Bank enabling us to continue investing in our existing companies and expand our portfolio of new biotechs, advancing our mission to develop the next generation of cancer therapies."
